Relmada Therapeutics appoints Fabiana Fedeli to board of directors

RELMADA THERAPEUTICS, INC.

Board expanded from 5 to 6 members; Fedeli appointed Class I director effective Jan 12, 2023.
Annual cash compensation: $66k as director, $9.9k audit committee, $7.7k compensation committee.
Granted option to buy 200,000 shares at $4.22, vesting over 4 years, subject to shareholder approval.
Fedeli is Chief Investment Officer at M&G Investments and was named in Financial News' 100 Most Influential Women in Finance.

item 1.01 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Fabiana Fedeli

Director

RLMD · RELMADA THERAPEUTICS, INC.

Effective: 2023-01-12
Filed: January 17, 2023, 6:59 PM ET

increased the number of directors constituting the whole board from five to six and appointed Fabiana Fedeli as a Class I director of the Company

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Fabiana Fedeli was appointed as Director at RELMADA THERAPEUTICS, INC..

Action: appointed
Role: Director

Exact text from the filing

increased the number of directors constituting the whole board from five to six and appointed Fabiana Fedeli as a Class I director of the Company

View on SEC.gov

RELMADA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-23-002865

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.